InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $7.43.

Several brokerages have commented on IFRX. Zacks Research downgraded InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. Needham & Company LLC began coverage on InflaRx in a research report on Monday, September 14th. They set a “buy” rating and a $8.00 price target on the stock. Cantor Fitzgerald raised their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday.

InflaRx Price Performance

Shares of IFRX stock opened at $1.93 on Friday. The stock has a market capitalization of $284.42 million, a price-to-earnings ratio of -3.33 and a beta of 2.52. The company’s fifty day simple moving average is $2.00 and its two-hundred day simple moving average is $1.82. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Equities research analysts anticipate that InflaRx will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. AXQ Capital LP bought a new stake in shares of InflaRx during the 2nd quarter valued at about $41,000. Montanova Capital LLC lifted its holdings in shares of InflaRx by 189.1% in the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock worth $51,372,000 after acquiring an additional 15,000,000 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of InflaRx in the 2nd quarter valued at $1,737,000. ADAR1 Capital Management LLC purchased a new stake in shares of InflaRx in the 2nd quarter valued at $6,720,000. Finally, Spruce Street Capital LP bought a new position in shares of InflaRx during the 2nd quarter valued at $11,988,924. 42.39% of the stock is owned by institutional investors.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company’s research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage.

InflaRx’s lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system.